Shares of the company are trading at $4.74 which is well above $4.30, the stock’s 50 day moving average and which is a tad above the 200 day moving average of $4.32. The 50 day moving average went up by +10.10% and the 200 day average went up $0.42 or +9.84%. Trading volume for icad inc. was 17K on Tuesday. Trading volume was down 41.35% under the stocks average daily volume.
Investors are feeling more bearish on the company if you pay attention to the rise in short interest. The stock recorded a rise in short interest of 36.06% between September 29, 2017 and October 13, 2017. Short interest grew from 39,551 to 53,813 over that timeframe. With short interest at 53,813 and short average daily volume at 38,068, the short-interest ratio is 1.0 and the percentage of shorted shares is 0.00% as of October 13.
Here are a few substantial investment firms who have updated their positions. As of the end of the quarter Tower Research Capital LLC (trc) had acquired a total of 202 shares growing its stake by 21.1%. The value of the investment in icad inc. decreased from $5,000 to $5,000 a change of $0 quarter to quarter. As of quarter end Drw Securities, LLC had bought 2,224 shares growing its position 17.1%. The value of the investment in (ICAD) went from $63,000 to $64,000 increasing 1.6% for the reporting period.
Spark Investment Management LLC grew its position by buying 3,900 shares an increase of 25.3% as of 06/30/2017. Spark Investment Management LLC owns 19,300 shares with a value of $80,000. The value of the position overall is down by 0.0%. As of the end of the quarter Bank Of Montreal /can/ had bought a total of 7,000 shares growing its holdings by 107.7%. The value of the investment in ICAD went from $27,000 to $60,000 a change of 122.2% quarter over quarter.
In the last earnings report the EPS was $-0.56 and is estimated to be $-0.54 for the current year with 16,594,000 shares currently outstanding. Next quarter’s EPS is estimated at $-0.08 with next year’s EPS anticipated to be $-0.22.
iCAD, Inc., launched on February 24, 1984, is a provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer. The Company provides image analysis and clinical decision support solutions for mammography, Magnetic Resonance Imaging (MRI) and Computed Tomography (CT) imaging. The Company operates in two segments: Cancer Detection (Detection) and Cancer Therapy (Therapy). The Detection segment consists of the Business’s advanced image analysis and workflow products, and the Therapy segment consists of its radiation therapy products. The Company sells its products throughout the world through its direct sales organization, as well as through various original equipment manufacturer (OEM) partners, distributors and resellers..